Director, HCP Marketing - Medical Education and KOL Strategy, Alzheimer’s Disease Psychosis

At Bristol Myers Squibb, our employees often ask, “Who are you working for?”—a question that fuels collaboration, accountability, and urgency in our work. Our purpose-driven culture inspires us to discover, develop, and deliver innovative medicines to prevail over serious diseases. We offer uniquely interesting and meaningful work, opportunities for growth, and a supportive environment that values inclusion, wellbeing, flexibility, and comprehensive benefits.

This is work that transforms the lives of patients, and the careers of those who do it.

Summary:

Bristol Myers Squibb is building a leading Neuroscience franchise focused on addressing areas of significant unmet need across serious neuropsychiatric and neurodegenerative diseases.

The Director, HCP Marketing, Medical Education, & KOL Strategy, Alzheimer's Disease Psychosis (ADP) will be responsible for developing and executing the U.S. KOL engagement strategy, medical education programming, peer-to-peer promotional activities, and congress commercial strategy for the anticipated launch of ADP, a potential first-in-class, first-approved treatment for AD psychosis and BMS's inaugural commercial entry into Alzheimer's disease.

This role is responsible for how BMS's pre- and post-launch disease and product education reaches external stakeholders: through the right thought leaders, at the right scientific forums, and via professionally executed promotional and educational programs that drive meaningful shifts in HCP understanding and behavior. The Director will build and manage the relationships, programs, and systems that allow BMS to show up credibly, compliantly, and consistently at the intersection of commercial education and medical influence across a complex, multi-specialty ADP HCP  partnership with Medical and the Regional Marketing Team, this role will be critical in identifying and activating KOLs, owning the annual congress strategy and execution, developing and managing peer-to-peer and speaker bureau programs, and building the operational infrastructure for KOL engagement across psychiatry, neurology, geriatrics, geriatric psychiatry, primary care, and LTC settings.

The Director must be able to operate in a fast-paced organization, with high expectations and accountability on quality of deliverables, and bring a bias for action, strong execution discipline, and a compliance-first mindset to all programs. The ability to establish strong partnerships with Medical Affairs (particularly MSLs and Home Office Medical), Commercial colleagues, Congress Management team, and external agencies is essential.

This role will support the investigational indication (Alzheimer's Disease Psychosis – ADP), which is currently under development and has not yet been approved by the FDA.Responsibilities:

KOL Engagement Strategy & Execution Develop and own the annual U.S. KOL engagement plan for ADP, including identification and tiered prioritization of thought leaders across the multi-specialty HCP landscape (psychiatrists, neurologists, geriatricians, geriatric psychiatrists, PCPs, NPs/PAs, and LTC medical directors)
Build and manage trusted, long-term relationships with priority KOLs and emerging thought leaders, positioning BMS as a credible, science-forward partner in a new disease area for the company

Partner closely with Medical Affairs (MSL team and Medical Directors) to ensure commercial and medical KOL engagement is coordinated, clearly delineated, compliant, and mutually reinforcing — maximizing the collective impact of BMS's external scientific engagement

Plan and execute commercial KOL programs, including advisory boards, promotional speaker development, and peer-to-peer educational events — ensuring timely insight capture and actionable…